{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:21:25Z","timestamp":1782937285407,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-invasive neuromodulation presents as an exciting potential adjunctive therapy for people with drug-resistant epilepsy (DRE). A major advantage of this approach is the absence of the neurocognitive and systemic adverse events commonly associated with anti-seizure medications (ASM), and the significant risks that accompany both resective epilepsy surgery and invasive neuromodulation techniques. The proposed systematic review and meta-analysis will investigate the efficacy of repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), low-intensity focused ultrasound (LI-FUS), transcutaneous vagus nerve stimulation (tVNS), and trigeminal nerve stimulation (TNS) for seizure reduction amongst patients diagnosed with DRE, with comparisons also being made between intervention types where applicable. Both immediate and long-term adverse events will also be discussed to offer greater insight into its use as a safe, viable, and reliable method of seizure control. The study\u2019s secondary aim will be to identify optimal stimulation parameters to better inform future clinical trial protocols and to maximise treatment efficacy in clinical applications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, OVID Embase, OVID Medline, and Web of Science will be searched for studies investigating the efficacy and safety of non-invasive nerve and brain stimulation techniques for the management of DRE. Two authors will independently screen relevant studies in Covidence, extract data, and assess risks of bias, with discrepancies being resolved by a third reviewer. The primary outcome will be seizure reduction, measured by mean\/median change in seizure frequency and responder rate. Secondary outcomes will include the percentage of patients reporting specified adverse events. A meta-analysis will assess the primary outcome. Subgroup analyses will be performed to investigate potential sources of heterogeneity and the optimal protocol settings for each intervention. Sensitivity analyses will also be conducted to evaluate the robustness of the results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study will analyse all relevant non-invasive brain and nerve stimulation methods using a consistent protocol, uniquely allowing for rigorous comparisons and result-pooling to evaluate the overall efficacy and safety of each stimulation method. Additionally, it will identify optimal stimulation parameters, where possible, to facilitate the use of these methods in future trials and clinical applications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>PROSPERO CRD42023446051.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13643-025-02981-2","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T14:55:26Z","timestamp":1762440926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Non-invasive neuromodulation for the treatment of drug-resistant epilepsy: Protocol for a systematic review and meta-analysis investigating efficacy, safety, and optimal stimulation parameters"],"prefix":"10.1186","volume":"14","author":[{"given":"Sayumi","family":"Premaratne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Zoghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Antonic-Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Hamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Major","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"H. X. Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"J. O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"N. Lundstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8695-1904","authenticated-orcid":false,"given":"Hugh","family":"D. Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"2981_CR1","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1212\/WNL.0000000000003509","volume":"88","author":"KM Fiest","year":"2017","unstructured":"Fiest KM, Sauro KM, Wiebe S, Patten SB, Kwon C-S, Dykeman J, et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology. 2017;88:296\u2013303. https:\/\/doi.org\/10.1212\/WNL.0000000000003509.","journal-title":"Neurology"},{"key":"2981_CR2","volume-title":"Epilepsy: a public health imperative","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. Epilepsy: a public health imperative. Geneva: World Health Organization; 2019."},{"issue":"3","key":"2981_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","volume":"75","author":"Z Chen","year":"2018","unstructured":"Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75:279. https:\/\/doi.org\/10.1001\/jamaneurol.2017.3949.","journal-title":"JAMA Neurol"},{"key":"2981_CR4","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1007\/s00415-023-12165-4","volume":"271","author":"R Shankar","year":"2024","unstructured":"Shankar R, Marston XL, Danielson V, Do Rego B, Lasagne R, Williams O, et al. Real-world evidence of epidemiology, patient characteristics, and mortality in people with drug-resistant epilepsy in the United Kingdom, 2011\u20132021. J Neurol. 2024;271:2473\u201383. https:\/\/doi.org\/10.1007\/s00415-023-12165-4.","journal-title":"J Neurol"},{"key":"2981_CR5","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1212\/WNL.0000000000011839","volume":"96","author":"B Sultana","year":"2021","unstructured":"Sultana B, Panzini M-A, Veilleux Carpentier A, Comtois J, Rioux B, Gore G, et al. Incidence and prevalence of drug-resistant epilepsy: a systematic review and meta-analysis. Neurology. 2021;96:805\u201317. https:\/\/doi.org\/10.1212\/WNL.0000000000011839.","journal-title":"Neurology"},{"issue":"6","key":"2981_CR6","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","volume":"51","author":"P Kwan","year":"2010","unstructured":"Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia. 2010;51(6):1069\u201377. https:\/\/doi.org\/10.1111\/j.1528-1167.2009.02397.x.","journal-title":"Epilepsia"},{"key":"2981_CR7","doi-asserted-by":"crossref","unstructured":"Bjellvi J, Olsson I, Malmgren K, Wilbe Ramsay K. Epilepsy duration and seizure outcome in epilepsy surgery: a systematic review and meta-analysis. Neurology. 2019;93. https:\/\/doi.org\/10.1212\/WNL.0000000000007753.","DOI":"10.1212\/WNL.0000000000007753"},{"key":"2981_CR8","doi-asserted-by":"publisher","first-page":"108951","DOI":"10.1016\/j.yebeh.2022.108951","volume":"137","author":"JL Alcala-Zermeno","year":"2022","unstructured":"Alcala-Zermeno JL, Gregg NM, Starnes K, Mandrekar JN, Van Gompel JJ, Miller K, et al. Invasive neuromodulation for epilepsy: comparison of multiple approaches from a single center. Epilepsy Behav. 2022;137:108951. https:\/\/doi.org\/10.1016\/j.yebeh.2022.108951.","journal-title":"Epilepsy Behav"},{"key":"2981_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/WCO.0000000000001138","volume":"36","author":"BN Lundstrom","year":"2023","unstructured":"Lundstrom BN, Osman GM, Starnes K, Gregg NM, Simpson HD. Emerging approaches in neurostimulation for epilepsy. Curr Opin Neurol. 2023;36:69\u201376. https:\/\/doi.org\/10.1097\/WCO.0000000000001138.","journal-title":"Curr Opin Neurol"},{"key":"2981_CR10","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1111\/epi.17329","volume":"63","author":"HD Simpson","year":"2022","unstructured":"Simpson HD, Schulze-Bonhage A, Cascino GD, Fisher RS, Jobst BC, Sperling MR, et al. Practical considerations in epilepsy neurostimulation. Epilepsia. 2022;63:2445\u201360. https:\/\/doi.org\/10.1111\/epi.17329.","journal-title":"Epilepsia"},{"key":"2981_CR11","doi-asserted-by":"crossref","unstructured":"Starnes K, Schulze-Bonhage A, Lundstrom B. Noninvasive brain stimulation for epilepsy, in: Neurostimulation for Epilepsy. Elsevier, 2023 pp. 175\u2013194. https:\/\/doi.org\/10.1016\/B978-0-323-91702-5.00012-8.","DOI":"10.1016\/B978-0-323-91702-5.00012-8"},{"key":"2981_CR12","doi-asserted-by":"crossref","unstructured":"Walton D, Spencer DC, Nevitt SJ, Michael BD. Transcranial magnetic stimulation for the treatment of epilepsy. Cochrane Database of Systematic Reviews 2021. 2021. https:\/\/doi.org\/10.1002\/14651858.CD011025.pub3.","DOI":"10.1002\/14651858.CD011025.pub3"},{"key":"2981_CR13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000206380","volume":"102","author":"Y Hawas","year":"2024","unstructured":"Hawas Y, Alkhawaldeh I, Alsalhi H, Matin R, Ibrahim G, Negida A. Transcranial direct current stimulation (tDCS) in treatment of refractory epilepsy: a systematic review and meta-analysis (P3\u20131.011). Neurology. 2024;102:6299. https:\/\/doi.org\/10.1212\/WNL.0000000000206380.","journal-title":"Neurology"},{"key":"2981_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.seizure.2021.01.020","volume":"86","author":"P Sudbrack-Oliveira","year":"2021","unstructured":"Sudbrack-Oliveira P, Barbosa MZ, Thome-Souza S, Razza LB, Gallucci-Neto J, Da Costa Lane Valiengo L, et al. Transcranial direct current stimulation (tDCS) in the management of epilepsy: a systematic review. Seizure. 2021;86:85\u201395. https:\/\/doi.org\/10.1016\/j.seizure.2021.01.020.","journal-title":"Seizure"},{"key":"2981_CR15","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.brs.2021.06.003","volume":"14","author":"JM Stern","year":"2021","unstructured":"Stern JM, Spivak NM, Becerra SA, Kuhn TP, Korb AS, Kronemyer D, et al. Safety of focused ultrasound neuromodulation in humans with temporal lobe epilepsy. Brain Stimul. 2021;14:1022\u201331. https:\/\/doi.org\/10.1016\/j.brs.2021.06.003.","journal-title":"Brain Stimul"},{"key":"2981_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/ans.15681","volume":"90","author":"K Wu","year":"2020","unstructured":"Wu K, Wang Z, Zhang Y, Yao J, Zhang Z. Transcutaneous vagus nerve stimulation for the treatment of drug-resistant epilepsy: a meta-analysis and systematic review. ANZ J Surg. 2020;90:467\u201371. https:\/\/doi.org\/10.1111\/ans.15681.","journal-title":"ANZ J Surg"},{"key":"2981_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.seizure.2021.05.017","volume":"91","author":"M Lampros","year":"2021","unstructured":"Lampros M, Vlachos N, Zigouris A, Voulgaris S, Alexiou GA. Transcutaneous vagus nerve stimulation (t-VNS) and epilepsy: a systematic review of the literature. Seizure. 2021;91:40\u20138. https:\/\/doi.org\/10.1016\/j.seizure.2021.05.017.","journal-title":"Seizure"},{"key":"2981_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1. https:\/\/doi.org\/10.1186\/2046-4053-4-1.","journal-title":"Syst Rev"},{"key":"2981_CR19","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;n71. https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"2981_CR20","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1398-9995.2009.01973.x","volume":"64","author":"JL Bro\u017cek","year":"2009","unstructured":"Bro\u017cek JL, Akl EA, Alonso-Coello P, Lang D, Jaeschke R, Williams JW, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines: part 1 of 3. an overview of the GRADE approach and grading quality of evidence about interventions. Allergy. 2009;64:669\u201377. https:\/\/doi.org\/10.1111\/j.1398-9995.2009.01973.x.","journal-title":"Allergy"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-025-02981-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-025-02981-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-025-02981-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T14:55:41Z","timestamp":1762440941000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-025-02981-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2981"],"URL":"https:\/\/doi.org\/10.1186\/s13643-025-02981-2","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"23 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BL declares intellectual property licensed to Cadence Neuroscience Inc (contractual rights waived; all funds to Mayo Clinic) and Seer Medical Inc (contractual rights waived; all funds to Mayo Clinic), site investigator (Medtronic EPAS, Neuroelectrics tDCS for Epilepsy), and industry consultant (Epiminder, Medtronic, Neuropace, Philips Neuro; all funds to Mayo Clinic). RH is a consultant for Nexstim (Helsinki, Finland). None declared otherwise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"214"}}